Company Overview
NuCana plc operates as a clinical-stage biopharmaceutical company dedicated to developing medicines for cancer patients within the United States. The company utilizes its proprietary ProTide technology to convert prescribed chemotherapy agents and nucleoside analogs into active therapeutic medicines, specifically targeting oncology indications. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself as a developer of novel drug delivery solutions. NuCana currently maintains a market capitalization of $5.83M and employs a workforce of 10 individuals, while its annual revenue is not publicly disclosed as a specific figure. The extremely small market cap relative to the typical biotechnology industry suggests the company is in an early-stage development phase where capital allocation is heavily weighted toward research and product formulation rather than commercial scale-up. The absence of reported annual revenue indicates that the company has not yet generated significant commercial sales, which is characteristic of clinical-stage entities focused on advancing pipeline assets through regulatory pathways before market entry.
Financial Health
The company reports a Net Income (TTM) of $-29,353,000 and an EBITDA of $-20,604,000, reflecting substantial operating losses typical for pre-revenue biotechnology firms. Although specific revenue figures are not listed, the significant negative net income compared to the EBITDA loss reveals a heavy cost structure driven by R&D expenses, general administrative costs, and potentially stock-based compensation that exceeds core operational cash burn. Free Cash Flow stands at $-3,824,625, indicating that the company consumes cash to fund its operations and development activities, thereby limiting immediate financial flexibility for external expansion or acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which indicates that the company has not yet achieved commercial profitability or that its current cost of goods sold and operating expenses fully absorb any generated revenue. The balance sheet shows a cash position of $24.25M against total debt of $676,000, suggesting a conservative capital structure where liquidity significantly outweighs liability obligations. The Debt to Equity ratio of 2.78 further contextualizes the leverage, while the Current Ratio of 5.60 demonstrates strong short-term liquidity, ensuring the company can meet its current liabilities with ease despite the cash burn. Return on Equity is -193.9% and Return on Assets is -58.3%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a necessary condition for clinical-stage development but one that highlights the high risk associated with the equity investment.
Valuation Assessment
The Trailing Twelve Month P/E Ratio is listed as N/A due to negative earnings, while the Forward P/E is -0.15, implying that the market prices the stock based on anticipated future earnings recovery or a specific valuation methodology that accounts for the negative earnings trajectory. The Price to Book ratio is 0.18, indicating that the market values the company at a fraction of its book value, which often occurs when assets are heavily weighted toward intangible R&D investments that are not fully captured on the balance sheet. The Price to Sales ratio is N/A as there is no reported revenue, and the EV/EBITDA stands at -1412.81, suggesting that traditional valuation multiples are not applicable and the stock price is decoupled from current earnings power or sales generation. The 52-week high is $268.00 and the 52-week low is $1.39, meaning the current price sits in the lower portion of its trading range relative to its historical volatility over the past year. The Beta value of 1.71 indicates that the stock is significantly more volatile than the broader market, with price movements expected to be nearly double the magnitude of general market fluctuations, reflecting the high risk profile of small-cap biotechnology equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet established a track record of commercial sales to calculate year-over-year percentage changes. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue because neither metric currently exists in a positive form to allow for such comparison. NuCana does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the company retains all available cash flow to reinvest into its clinical development programs and operational infrastructure. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize pipeline advancement over shareholder distributions. The overall growth and income profile is characterized by a complete absence of commercial income generation, relying entirely on the successful execution of clinical trials and regulatory approvals to transition from a cash-burning clinical-stage entity to a revenue-producing biopharmaceutical business.